

## Evaluation Report for Category B, Subcategory 3.1 Application

**Application Number:** 2021-0093  
**Application:** Changes ISP Product Chemistry- Specifications  
**Product:** Myacide GDA Technical Microbiocide  
**Registration Number:** 26218  
**Active ingredients (a.i.):** Glutaraldehyde  
**PMRA Document Number:** 3372438

### Purpose of Application

The purpose of this application was to revise the suppliers of starting materials, provide new batch data, and to update the specifications.

### Chemistry Assessment

Common Name: Glutaraldehyde  
IUPAC\* Chemical Name: Pentanedial  
CAS† Chemical Name: 1,5-Pentanedial

\* International Union of Pure and Applied Chemistry

† Chemical Abstracts Service

Myacide GDA Technical has the following properties:

| Property                              | Result                           |
|---------------------------------------|----------------------------------|
| Colour and physical state             | Colourless to pale yellow liquid |
| Nominal concentration                 | 50.0%                            |
| Odour                                 | Characteristic of aldehydes      |
| Density                               | 1.13 g/cm <sup>3</sup>           |
| Vapour pressure                       | 133 Pa                           |
| pH                                    | 3.2-4.2                          |
| Solubility in water                   | Miscible                         |
| n-Octanol/water partition coefficient | Log K <sub>ow</sub> = -0.22      |

The required chemistry data for Myacide GDA Technical Microbiocide have been provided, reviewed, and found to be acceptable.

### **Health, Environmental and Value Assessments**

Health, environmental, and value assessments were not required for this application.

### **Conclusion**

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support the revisions to Myacide GDA Technical Microbiocide.

## References

| <b>PMRA Document Number</b> | <b>Reference</b>  |
|-----------------------------|---|
| 3188485                     | 2016, Product Chemistry Group A: Myacide GDA Technical EPA Reg 33753-23, DACO: 2.11,2.11.2,2.11.3,2.11.4,2.12,2.12.1,2.13 CBI           |
| 3188486                     | 2015, Characterization of "5 batches of Protectol GA 50", DACO: 2.13.3 CBI  |
| 3293023                     | 2021, Description of Starting Materials: Myacide GDA Technical, DACO: 2.11.2 CBI  |
| 3334976                     | 2022, Establishing Limits [CBI Removed] in Myacide GDA Technical Microbicide PCP# 26218, DACO: 2.12,2.12.1 CBI                          |
| 3334977                     | 2022, Myacide GDA - Q-analysis data 2016 - 2022 [CBI Removed], DACO: 2.13.3 CBI   |
| 3334978                     | 1998, Product Chemistry Myacide GDA Technical, DACO: 2.11.3,2.11.4 CBI  |
| 3334979                     | 2000, Product Chemistry for Gluteraldehyde (50% solution) Series 62 - Preliminary Analysis, DACO: 2.13.1 CBI                            |
| 3334980                     | 2004, Determination of [CBI Removed] "protectol GA 50" for the notification in the netherlands, DACO: 2.13.1 CBI                        |
| 3334981                     | 2004, Characterization of "protectol GA 50" for the notification in the Netherlands, DACO: 2.13.2 CBI                                   |
| 3334982                     | 2017, Physico-chemical Properties of Protectol GA 50 over 2 Years at 20 C, DACO: 2.14.14 CBI  |
| 3343261                     | 2022, Waiver - Water batch data, DACO: 2.13.3 CBI   |
| 3363816                     | 2022, Linearity titration curve for GA 19042022, DACO: 2.13.1 CBI   |
| 3363817                     | 2006, Characterization of "Protectol GA 50" before start of toxicological and endpoint studies, DACO: 2.13.2 CBI                        |
| 3363818                     | 2022, 1st Amendment to final report Characterization of "5 batches Protectol GA 50" Study No. 15L00244 (Confidential), DACO: 2.13.3 CBI |

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2022

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.